


The effect of disease onset chronology on mortality among patients with multimorbidity: A Danish nationwide register study

Journal of Multimorbidity and Comorbidity
Volume 12: 1–10
© The Author(s) 2022
Article reuse guidelines:
sagepub.com/journals-permissions
DOI: 10.1177/26335565221122025
journals.sagepub.com/home/cob


Tora G Willadsen¹ , Volkert Siersma¹, Dagny R Nicolaisdóttir¹, Rasmus Køster-Rasmussen¹, Susanne Reventlow¹ and Maarten Rozing¹

Abstract

Background: Multimorbidity is associated with increased mortality. Certain combinations of diseases are known to be more lethal than others, but the limited knowledge of how the chronology in which diseases develop impacts mortality may impair the development of effective clinical interventions for patients with multimorbidity.

Objective: To explore if in multimorbidity the chronology of disease onset is associated with mortality. Design: A prospective nationwide cohort study, including 3,986,209 people aged ≥ 18 years on 1 January 2000, was performed. We included ten diagnosis groups: lung, musculoskeletal, endocrine, mental, cancer, neurological, gastrointestinal, cardiovascular, kidney, and sensory organs. We defined multimorbidity as the presence of at least two diagnoses from two diagnosis groups (out of ten). To determine mortality, logistic regression models were used to calculate odds ratios (OR) and ratio of ORs (RORs).

Results: For most combinations of multimorbidity, the chronology of disease onset does not change mortality. However, when multimorbidity included mental health diagnoses, mortality was in general higher if the mental health diagnosis appeared first. If multimorbidity included heart and sensory diagnoses, mortality was higher if these developed second. For the majority of multimorbidity combinations, there was excess mortality if multimorbidity was diagnosed simultaneously, rather than consecutively, for example, heart and kidney (3.58 ROR; CI 2.39–5.36), or mental health and musculoskeletal diagnoses (2.38 ROR; CI 1.70–3.32).

Conclusions: Overall, in multimorbidity, the chronology in which diseases develop is not associated with mortality, with few exceptions. For almost all combinations of multimorbidity, diagnoses act synergistically in relation to mortality if diagnosed simultaneously.

Keywords

Multimorbidity, mortality, chronology, disease onset, cohort study, register study

Received 18 March 2022; revised 9 June 2022; accepted: 2 August 2022

¹Section of General Practice and Research Unit for General Practice, Department of Public Health, University of Copenhagen, Copenhagen, Denmark

Introduction

The prevalence of multimorbidity, defined as the co-occurrence of at least two chronic conditions in one person,¹ is increasing.^{2,3} In general practice, about one-third of

Corresponding author:

Tora G Willadsen, Section of General Practice and the Research Unit for General Practice, Department of Public Health, University of Copenhagen, Øster Farimagsgade 5, Copenhagen DK-1353, Denmark.
Email: tora.willadsen@sund.ku.dk



Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (<https://creativecommons.org/licenses/by-nc/4.0/>) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (<https://us.sagepub.com/en-us/nam/open-access-at-sage>).

patients have ≥ 4 chronic conditions, and many patients develop chronic conditions over the course of life.⁴ The dynamics of multimorbidity mean that its prevalence increases with age,^{5–8} but at the same time, most people with multimorbidity are actually below 65 years of age.⁹ It has long been established that multimorbidity confers an increased mortality risk,^{7,10,11} and that life expectancy decreases with the number of chronic conditions.¹² Accordingly, we earlier found a dose–response relationship between the number of chronic conditions and mortality.⁷

The association between multimorbidity and mortality is more heterogeneous than the above broad characterization implies. Earlier, we showed that certain multimorbidity combinations conferred particularly high mortality.⁷ However, some of these particularly detrimental combinations appear to differ between men and women, and are probably modified by various other factors.^{7,13} The development of multimorbidity may follow myriad trajectories in which some people stay free of chronic conditions until late in life, while others develop numerous conditions at a higher speed,^{14,15} for example, centenarians have a slower pace of developing multimorbidity than non-centenarians.¹⁶ Furthermore, the unique trajectories have different implications, for example, a person with a mental health diagnosis that years later develops a lung disease due to smoking compared to a person that develops a mental health condition in the aftermath of heart disease. Both scenarios are central for the care delivered in general practice and contain both ongoing preventive work and also work into understanding of the nature and complications that can evolve because of new diseases. The need for understanding the implications of the development of multimorbidity in a life course perspective has been emphasized.^{10,17} Still, there is not much investigation into the temporal order in which the onset of diseases becomes multimorbidity and its consequences for mortality.

To improve health care for people with multimorbidity, interventions have to focus on areas of certain needs. By gaining knowledge about the association between disease chronology and mortality in multimorbidity, interventions not only can be targeted at combinations of certain diseases but also improve the timing of preventive measures.

Objective

This study has two objectives:

1. To explore if mortality differs among multimorbidity combinations with a different chronology.
2. To estimate the excess mortality from having multimorbidity (i.e., the joint effect of two conditions compared to the effect of the conditions individually) with different chronology.

Material and methods

Study design and population

The study included the entire Danish adult population (aged ≥ 18 years) on 1 January 2000 (baseline). The cohort was previously created⁷ and extracted from the Danish Civil Registration System (CRS)¹⁸ and was prospectively followed for 15 years until 31 December 2014 (Figure 1). At baseline, background characteristics age, sex, socioeconomic status (family income, highest completed education, work status, and assets), degree of urbanization, and cohabitation status were identified. To estimate the level of multimorbidity at baseline, information on all diagnoses leading to either inpatient or outpatient care contacts was obtained from the Danish National Patient Register (NPR) in the ten years before baseline (1 January 1990 until 31 December 1999). If patients migrated or were lost to follow-up during this period, they were excluded (Figure 1). Fifteen-year all-cause mortality was our outcome. Also emigration and loss to follow-up in the 15 years after baseline led to exclusion.

Nationwide registries

All (live) born children, as well as new residents in Denmark, receive a unique personal identification number, which is stored in CRS.¹⁸ The identification number makes it possible to link personal information from all Danish registries. The administrative purposes of CRS ground weekly updates and continuous corrections of errors. Because Danish law requires registration in CRS, the information is assumed to be of high quality. Information on vital status, emigration, family connections is provided by CRS.¹⁸ The NPR,¹⁹ the Danish Cancer Registry (CR),²⁰ and the Danish Psychiatric Central Research Register (PCRR)²¹ provided the study with information about diagnoses. Outpatient care and emergency admissions, however, were first included in 1995. In NPR, the diagnostic information is coded as International Classification of Diseases, 10th edition (ICD-10), and until 1994, the earlier version 8th edition (ICD-8).²² All incident cancers in Denmark, since 1943, are included in CR, and since 1978, they are coded as ICD-10 codes.²⁰ In PCRR, all patients having mental health diseases and in need of secondary health care at public hospitals are registered with ICD codes.²¹ To be included with diagnoses from CR and PCRR, only information on whether a patient appears in the register, in the ten-year period before baseline, was required. Information on socioeconomic status, that is, income,²³ education,²⁴ work status,²⁵ and assets,²³ was retrieved from Statistics Denmark's registers. Since the study used anonymized administrative register data, neither approval from the Ethics Committee nor informed consent from the study




Figure 1. The population through study.

participants was required. The Danish Data Protection Agency, The Danish Health Data Authority, and Statistics Denmark approved the study.

Definition of multimorbidity

Multimorbidity in this study is based on ten groups of diagnoses: lung, musculoskeletal, endocrine, mental health, cancer, neurological, gastrointestinal, cardiovascular, genitourinary, and sensory organs. Each group contains several diagnoses that to some level share treatments, clinical picture, or organization of health care ([Supplementary File 1](#)), for example, the lung diagnosis group contains chronic obstructive pulmonary disease (COPD) (found in the Danish national health registers as ICD-10 code J44 or ICD-8 code 490), chronic bronchitis (J41-42; 491), emphysema (J43; 492), and asthma (J45-46; 493). Lung diagnoses were seen among 2.5% of the population ([Supplementary File 2](#)). Persons were defined as having multimorbidity, if diagnoses from at least two different groups, out of the ten, were present. Diagnoses included in the ten groups covered frequent conditions in the population and were selected based on clinical relevance, earlier definitions of multimorbidity^{9,26} and systematic reviews.^{22,27–30} We assumed that a combination of conditions that differ in how they are treated and managed in the health care system may be organizationally and physiologically more complicated. Therefore, we consider that groups of diagnoses, instead of individual diagnoses, better reflect the complexity related to multimorbidity. Prevalence of the included diagnoses in this study is listed in [Supplementary File 2](#).

Statistical analyses

For combinations of two diagnosis groups, there are three possible chronologies: one can appear before the other or vice versa, or they can appear simultaneously. With ten diagnosis groups, this gives $45 \times 3 = 135$ chronologized combinations. The association between 15-year mortality and chronology of multimorbidity was calculated by comparing the risks (all 135 combinations), compared to persons not in any of the ten diagnosis groups with odds ratios (ORs) from multivariable logistic regression. Adjustments were made for age, sex, socioeconomic status, degree of urbanization, and cohabitation status. To assess excess mortality, we calculated a synergy or susceptibility factor.³¹ This factor is calculated as a ratio of ORs ($ROR = OR_{A+B} / (OR_A \times OR_B)$). This means that if, for example, $ROR > 1$, there is higher mortality when two diagnosis groups appear in one person, compared to when the two diagnosis groups appear separately in two persons.³¹ As for a given combination of diagnosis groups, a separate OR_{A+B} is obtained for each of the three chronologies; excess mortality is also assessed by separate ROR for each chronology. We will focus our result section mainly on combinations with $ROR > 1$, but in some cases, combinations with $ROR < 1$ will be touched upon. SAS, version 9.4 (SAS Institute Inc., Cary, NC, USA) was used for statistical analyses.

Results

The population consisted of 3,986,209 persons at baseline. At the end of follow-up, 802,189 had died ([Figure 1](#)).

Table 1. Baseline characteristics of the Danish population by number of diagnosis groups.

Baseline ^a characteristics	0 diagnosis groups ^b , N = 2.943.205 (73.83%)		1 diagnosis group, N = 759.182 (19.05%)		2 diagnosis groups, N = 206.096 (5.17%)		3+ diagnosis groups, N = 77.726 (1.95%)		Total, N = 3.986.209 (100%)	
	N	%	N	%	N	%	N	%	N	%
Sex										
Male	1.486.037	50.5	344.667	45.4	91.189	44.3	33.224	42.7	1.955.117	49.1
Age, years										
18–39	1.301.845	44.2	186.928	24.6	23.050	11.2	3.359	4.3	1.515.182	38.0
40–64	1.251.062	42.5	336.354	44.3	77.692	37.7	22.260	28.6	1.687.368	42.3
65–79	313.398	10.7	165.386	21.8	66.501	32.3	22.362	39.1	575.651	14.4
80+	76.900	2.6	70.514	9.3	38.853	18.9	15.685	28.0	208.008	5.2
Education										
None	135.350	4.6	90.996	12.0	46.079	22.4	18.026	32.0	297.263	7.5
Primary school	949.414	32.3	293.242	38.6	84.190	40.9	23.659	40.5	1.358.332	34.1
Secondary school ^c	1.250.687	42.5	257.520	33.9	54.130	26.3	12.342	20.4	1.578.179	39.6
Higher educations ^d	607.754	20.7	117.424	15.5	21.697	10.5	4.427	7.2	752.435	18.9
Income ^e										
0–99.999	486.006	16.5	166.757	22.0	62.830	30.5	22.221	39.8	746.509	18.7
100.000–149.999	918.428	31.2	282.951	37.3	84.459	41.0	24.335	41.4	1.318.039	33.1
150.000–199.999	870.610	29.6	179.558	23.7	35.736	17.3	7.821	12.5	1.095.586	27.5
200.000+	668.161	22.7	129.916	17.1	23.071	11.2	4.077	6.3	826.075	20.7
Working status										
Working	2.065.190	70.2	331.180	43.6	44.154	21.4	5.548	8.1	2.446.799	61.4
Out of workforce ^f	416.188	14.1	171.745	22.6	52.779	25.6	14.436	24.4	659.705	16.6
Pensioners	461.827	15.7	256.257	33.8	109.163	53.0	38.470	67.5	879.705	22.1
Asset ^g										
<0	1.096.792	37.3	253.763	33.4	62.613	30.4	17.821	31.5	1.437.615	36.1
0–149.999	873.710	29.7	232.751	30.7	69.031	33.5	21.054	36.4	1.203.766	30.2
150.000+	972.703	33.1	272.668	35.9	74.452	36.1	19.579	32.2	1.344.828	33.7
Urbanization degree ^h										
Rural	1.012.167	34.4	261.615	34.5	71.130	34.5	19.411	32.7	1.370.361	34.4
Small town	1.077.357	36.6	272.407	35.9	71.506	34.7	19.611	33.1	1.446.980	36.3
Capital city	853.681	29.0	225.160	29.7	63.460	30.8	19.432	34.2	1.168.868	29.3
Cohabiting										
Yes	2.051.871	69.7	466.553	61.5	108.255	52.5	26.423	43.7	2.660.643	66.7

^a1 January, 2000.^bPresented as dichotomous variables in numbers (N) and percentages (%). No multimorbidity = 0 or 1 diagnosis group, multimorbidity = 2 or ≥3 diagnosis groups.^cSecondary school: secondary school, high school, and higher-level vocational studies.^dHigher educations: short and medium higher education or college diploma, university degree (bachelor or master), doctoral degree.^eIncome: divided into quartiles, yearly income in Danish kroner.^fOut of workforce: unemployed, student, apprentice or intern, or incapacity benefits.^gAssets: divided in tertiles, presented in Danish kroner, including stocks, bonds, savings in banks and housing, within and outside Denmark.^hRural: at least 50% of the population in the municipality lives in a thinly populated area. Small town: Intermediate density area. Less than 50% of the population lives in a densely populated area and less than 50% of the population lives in a thinly populated area. Capital: At least 50% of the population lives in a densely populated area.

Overall, 7.1% developed multimorbidity. Multimorbidity was more prevalent at a higher age, in women, in persons living alone, and in persons with low socioeconomic status (Table 1). The ten multimorbidity combinations with highest mortality (OR) and highest excess mortality (ROR) are listed in Table 2. Multimorbidity combinations

including musculoskeletal diagnoses were prevalent (1.8%) independent of chronology (Figure 2(a)–(c)) (Supplementary Files 3–6). Moreover, mortality was generally low for combinations including musculoskeletal diagnoses, though lowest if the musculoskeletal diagnosis came first (Figure 2(a) and (c)) (Supplementary Files 3 and

Table 2. The 10 diagnosis group combinations with highest mortality and excess mortality, respectively.

	Mortality (OR)	Diagnosis group combination
1	4.10 [3.90–4.29]	Mental-sensory*
2	3.72 [1.60–5.83]	Cancer-gastro (concurrently)
3	3.48 [3.39–3.57]	Heart-lung (concurrently)
4	3.45 [3.05–3.85]	Heart-kidney (concurrently)
5	3.38 [3.27–4.49]	Heart-neuro (concurrently)
6	3.38 [2.87–3.89]	Heart-sensory (concurrently)
7	3.38 [3.26–3.50]	Neuro-sensory*
8	3.34 [3.00–3.67]	Mental health-musculoskeletal (concurrently)
9	3.27 [3.20–3.35]	Heart-sensory*
10	3.27 [2.60–3.93]	Mental-sensory (concurrently)

	Excess mortality (ROR)	Diagnosis group combination
1	3.58 [2.39–5.36]	Kidney-heart (concurrently)
2	3.22 [2.07–5.01]	Kidney-musculoskeletal (concurrently)
3	2.64 [1.81–3.86]	Kidney-endo (concurrently)
4	2.58 [1.60–4.16]	Kidney-neuro (concurrently)
5	2.38 [1.70–3.32]	Musculoskeletal-mental (concurrently)
6	2.27 [1.86–2.77]	Musculoskeletal-lung (concurrently)
7	2.10 [1.02–4.30]	Kidney-gastro (concurrently)
8	1.80 [1.50–2.15]	Endo-gastro (concurrently)
9	1.74 [1.34–2.26]	Musculoskeletal-gastro (concurrently)
10	1.70 [1.22–2.36]	Lung-gastro (concurrently)

*Diagnosed in the presented chronology.

5). If the musculoskeletal diagnosis was diagnosed concurrently with other diagnoses, mortality was increased considerably for some combinations, for example, musculoskeletal and mental health (OR 3.34 [95% CI 3.00–3.67] with excess mortality of ROR 2.38 [95% CI 1.70–3.32]) (Figure 2(b)) (Supplementary Files 4 and 7).

Multimorbidity including heart diagnoses was prevalent (1.8%) and associated with considerably increased mortality, especially if the heart diagnosis occurred as the second diagnosis (Figure 2(a) and (c)) (Supplementary Files 3 and 5). If diagnosed concurrently, mortality was generally higher than if diseases were diagnosed over time (Figure 2(a)–(c)), especially in combination with lung diseases (OR 3.48 [95% CI 3.39–3.57] and ROR 1.54 [95% CI 1.41–1.70]) or kidney diseases (OR 3.45 [95% CI 3.05–3.85] and ROR 3.58 [95% CI 2.39–5.36]) (Figure 2(b)) (Supplementary Files 4 and 7).

Multimorbidity including sensory diagnoses was relatively common (1.1%) and was associated with high mortality, especially if it developed as the second disease. If diagnosed simultaneously with other diseases, lower excess mortality was observed for almost all combinations (Figure 2(b)) (Supplementary Files 4 and 7).

For multimorbidity including mental health diagnoses (0.6%), mortality was highest if the mental health diagnosis appeared as the first, for example, in combination with

sensory (OR 4.10 [95% CI 3.90–4.29] and ROR 1.35 [95% CI 1.11–1.64]) diagnoses (Figure 2(a) and (c)) (Supplementary Files 3 and 5). Furthermore, when diagnosed concurrently, excess mortality increased for three (only two were significant) out of ten combinations, where, for example, the combination mental health and neurological diseases had lower excess mortality (OR 2.65 [95% CI 2.51–2.79] and ROR 0.59 [95% CI 0.51–0.68]) (Figure 2(b)) (Supplementary Files 4 and 7).

Multimorbidity including gastroenterological and kidney diagnoses (0.7% and 0.3%, respectively) did not confer a higher risk of death when diagnosed at different points in time. However, if diagnosed concurrently, mortality and excess mortality increased for almost all combinations. Overall, diagnoses that were made simultaneously, rather than consecutively, had higher excess mortality for the vast majority of combinations (Figure 2(b)) (Supplementary Files 4 and 7).

Discussion

This study investigated, in the full Danish adult population, how the association between multimorbidity and mortality is affected by the order in which the diseases in different multimorbidity combinations are diagnosed. Overall, chronology has a small effect on the association between




Figure 2. Mortality risk associated with disease onset chronology in multimorbidity.

Panel (b) displays risks when two morbidities are diagnosed simultaneously, and panels (a) and (c) display risks when morbidities are diagnosed at different times. In panel (a), the first morbidity diagnosed is read from the y-axis (vertical) and the second is read from the x-axis (horizontal). In panel (c), the second morbidity is read from the y-axis and the first is read from the x-axis.

The size of the discs indicates frequencies, the gray to black scale indicates an increase in mortality (OR) (the darker color, the higher mortality increases relative to persons who do not have diagnoses), and the red/green auras around the discs indicate synergy or susceptibility factor (ROR). If $ROR < 1$, the aura is green, indicating reduced excess mortality for the combination. If $ROR > 1$, the aura is red, indicating increased excess mortality for the combination.

Reading example: If we look at the panel (a) at the combination LUNG and HEART, the LUNG diagnosis comes before the HEART diagnosis. Prevalence is approximately 2000 (size of the disc), mortality is around a threefold increase ($OR = 3$) (gray tone), and the excess mortality is increased (the aura is red) (exact numbers are to be found in the supplementary materials).

multimorbidity and mortality, except for heart, sensory, and mental health diagnoses, where mortality is higher if a mental health diagnosis comes first or if a heart or a sensory

comes second. Multimorbidity including heart diagnoses is particularly harmful when it concurs with either the lung or kidney. In general, excess mortality is higher if diagnosing

coincides compared to if diagnosing spreads over time, especially for gastroenterological and kidney diagnoses. However, sensory diagnoses are seldom diagnosed concurrently with other diagnoses, and if so, both mortality and excess mortality is comparably low (Figure 2(b)).

Comparison with existing literature

Trajectories of multimorbidity have received increasing interest,^{16,32–34} as have multimorbidity clusters³⁵ and their relation to mortality.^{7,34,36,37} However, this is the first study to explore how chronology affects the association between multimorbidity and mortality. The main findings of our study are twofold: overall, chronology does not have a consistent effect on the association between multimorbidity and mortality (with few exceptions) and excess mortality is higher for the majority of multimorbidity combinations when diagnoses are made at the same time.

In relation to the first finding, musculoskeletal diagnoses are both frequent and do not confer a high mortality risk, especially when the musculoskeletal diagnosis comes first. Musculoskeletal diagnoses are very prevalent among patients with multimorbidity.³⁸ However, the development of a musculoskeletal disorder in the presence of preexisting chronic conditions may result from a reduced physical performance and serve as a pathway to mortality.^{39,40} Multimorbidity including heart diagnoses is both prevalent and has higher mortality, especially if the heart disease is diagnosed second. Cardiovascular diseases often develop later in life or later in the multimorbidity trajectory.^{33,41} In our study, the combination of heart and lung disorders was associated with higher mortality, which may be because of residual confounding, for example, shared lifestyle risk factors such as smoking, which we were not able to control for. Mental health diagnoses are most harmful when they appear as the first diagnosis. Mental health conditions tend to appear at some point in the multimorbidity trajectory, with increasing risk with the number of somatic conditions^{9,41}; however, for some ethnic and younger age groups, depression is often the starting diagnosis.³³ Furthermore, there is a relation between mental health conditions and the development of later somatic conditions.⁴² Most severe and persistent mental disorders have an age of onset in the 20s and 30s; these mental disorders are risk indicators for somatic morbidity.⁴³ Severe mental health disorders reduce life expectancy by almost two decades.⁴⁴ This could probably be ascribed to several factors such as metabolic side effects of psychotropic medication and unhealthy lifestyle, but also shared genetic factors for the mental health disorders and some somatic conditions.⁴⁵

The second finding, that there is excess mortality ($ROR > 1$) if diagnoses coincide and $ROR < 1$ when the onsets are separated in time, could have several explanations. If patients are diagnosed with one condition and receive medical

attention for this condition, there is a higher chance that a second condition is found and often earlier in the course of the disease. The second disease is therefore often less severe than if it was found as the first.⁴⁶ Hence, for disease onsets separated in time, a $ROR < 1$ is expected. This means that detection bias to some extent is inherent to multimorbidity. Since many definitions of multimorbidity include risk factors,³¹ that is, conditions associated with a probability of disease,^{47,48} some patients, depending on the definition used, will be found even earlier in the disease trajectory.

For patients with multimorbidity, symptoms are frequent and the number of symptoms increases with the number of diagnoses.⁴⁹ At a certain point in the multimorbidity trajectory, or a certain speed in disease development, people become aware of sensations⁵⁰ and symptoms, sometimes overwhelming them,⁵¹ increasing the chance that a doctor contact is established.⁵² The simultaneous appearance of two or more diagnosis groups may also be the observation of the onset of systemic disease, which tends to be more hazardous or have some underlying etiology or pathology^{53,54} explaining the coincidence. Another explanation is that for a second condition to be discovered simultaneously with a first condition—which would be the focus of the hospital contact—it has to present itself prominently. Hence, this second condition will often be more dangerous than if it was found by itself. Conversely, especially since we use secondary sector data, the doctor's actions taken in relation to a symptom may increase the risk or chance that another diagnosis is detected, for example, a well-treated diabetes diagnosis with several years of duration may first be recorded in the secondary sector as an auxiliary diagnosis at the time for a hospital contact for another disease. An excess mortality may then appear when the diabetes is subsequently downplayed in light of the new condition.

Strengths and limitations

In this study, the use of a large nationwide cohort including the whole adult (≥ 18 years) Danish population is a strength and the sample size makes it possible to explore not only combinations of two diagnosis groups but also combinations of the two in a chronological perspective. It is well known that in the case of multimorbidity, mortality increases considerably with age,^{7,9} as well with the number of diagnoses,^{7,38} and especially from three or more diagnoses mortality increases steeply.¹² Therefore, if we had studied combinations of multimorbidity containing more than two diagnosis groups or had included another age group, we may have had other and stronger associations to mortality. Often, studies use a simple count of diseases when defining multimorbidity^{27,30,55}; however, in the present study, multimorbidity is defined based on diagnosis groups sharing similarities in how they are managed and treated in the

health care system. Hence, having multimorbidity according to this definition allows for an extra organizational aspect to be taken into account, why we believe complexity and burden of multimorbidity, but also the association to mortality is better grasped. The use of data from secondary care underestimates the prevalence of multimorbidity seen in general practice. On the other hand, we include diagnoses of a certain severity since a referral is required to get in contact with the secondary health system. Furthermore, the used registers are highly valid^{19,20} and no nationwide primary care register exists in Denmark. Using registers, we are not able to get information on important lifestyle factors, and even though we adjusted our results for important factors known to be a risk factor for developing and dying from multimorbidity,^{9,56} residual confounding can still be present. The risk of selection bias and sampling error is low. The large sample size allows for very precise estimation, with concomitantly low *p*-values, also for clinically less relevant associations; thus, interpretation has to be cautious.⁵⁷ It is a limitation that we did not consider the time passed between the first and the second diagnosis. However, when using diagnoses collected over a period of 10 years (prior to baseline), both incident and prevalent diagnoses are believed to be found, that is, with certain disease trajectories or be caught late in the course of the disease.⁵⁷ The independence between the prevalence of the outcome and OR is the primary reason for using logistic regression to assess the associations between chronology in multimorbidity and mortality. Furthermore, the ORs are directly comparable across the different multimorbidity combinations and across chronology, as well as they enable us to construct the RORs. In an earlier study, sensitivity analyses assuming all persons who were lost to follow-up were deceased did not change the conclusions.⁷

Implications

This study adds knowledge on how multimorbidity develops from a time perspective and how chronology influences mortality. This can be valuable when organizing care for patients with multimorbidity, especially if they have indications for prevention. In this sense, it is also important to have gained an understanding that chronology is not a major driver of mortality. Multimorbidity combinations including mental health conditions as the first diagnosis need extra attention (e.g., when diagnosing new conditions, planning tertiary prevention and care) because of the associated elevated mortality. Especially to focus on heart risk factors among patients with mental health conditions could be meaningful, and to target mental health conditions in relation to multimorbidity seems to be one of few successes in multimorbidity interventions until now.^{58,59} Furthermore, combined specialist clinics, or increased cooperation between the responsible hospital departments, for patients

having certain combinations of multimorbidity, for example, combinations including cardiovascular and lung diagnoses, could be valuable. Furthermore, this study stresses awareness of multimorbidity including diagnoses that are diagnosed at the same point in time because of the synergy in mortality risk they seem to contain. The large sample makes it possible to reveal valuable clinical implications, but this would require a focus on single conditions instead of groups of diagnoses. Therefore, some research implications of this study will be to look further into diagnoses in combinations that contain especially high excess mortality. Furthermore, we will explore what time (long vs short) between diagnoses means for mortality.

Conclusions

In general, the chronology in which diseases develop in multimorbidity is not associated with mortality, with a few exceptions for combinations including heart, sensory, and mental health diagnoses. This opens up for focus on preventive actions in order to mitigate some of the consequences of multimorbidity. Multimorbidity definitions are wide and diverse, and even in secondary care, the prevalence may partly be explained by the exposure to health care contacts among these patients, where conditions are found earlier in the disease trajectory. Finally, awareness is needed for diagnoses found concurrently since they act synergistically in relation to mortality, compared to multimorbidity found over time.

Author Contributions

T.G.W. designed, wrote, and edited the manuscript, researched the data, and contributed to the discussion. V.S. and D.R.N. performed the analyses, researched the data, contributed to the discussion, and reviewed/edited the manuscript. R.K.-R., S.R., and M.R. researched the data, made important contributions to the discussion and content, and reviewed/edited the manuscript. All authors approved the final version of the manuscript. T.G.W., V.S., and D.R.N. have full access to data and take full responsibility for the reliability and truthfulness of the data and the data analyses. T.G.W. is the guarantor of this work.

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by The Helsefonden, grant number 19-B-0173 and Fonden for Almen Praksis (A3515).

ORCID iD

Tora G Willadsen  <https://orcid.org/0000-0001-7240-1944>

Supplemental Material

Supplemental material for this article is available online.

References

- van der Akker M, Buntinx K and Knottnerus JA. Comorbidity or multimorbidity: what's in a name? a review of literature. *Eur J Gen Pract* 1996; 2: 65–70.
- van den Akker M, Vaes B, Goderis G, et al. Trends in multimorbidity and polypharmacy in the Flemish-Belgian population between 2000 and 2015. *PLoS One* 2019; 14(2): e0212046.
- Uijen AA and van de Lisdonk EH. Multimorbidity in primary care: prevalence and trend over the last 20 years. *Eur J Gen Pract* 2008; 14(Suppl 1): 28–32.
- Vos R, van den Akker M, Boesten J, et al. Trajectories of multimorbidity: exploring patterns of multimorbidity in patients with more than ten chronic health problems in life course. *BMC Fam Pract* 2015; 16: 2.
- Marengoni A, Angleman S, Melis R, et al. Aging with multimorbidity: a systematic review of the literature. *Ageing Res Rev* 2011; 10(4): 430–439.
- Salive ME. Multimorbidity in older adults. *Epidemiol Rev* 2013; 35: 75–83.
- Willadsen TG, Siersma V, Nicolaisdottir DR, et al. Multimorbidity and mortality: a 15-year longitudinal registry-based nationwide Danish population study. *J Comorb* 2018; 8(1): 2235042x18804063.
- Schiøtz ML, Stockmarr A, Høst D, et al. Social disparities in the prevalence of multimorbidity - a register-based population study. *BMC Public Health* 2017; 17(1): 422.
- Barnett K, Mercer SW, Norbury M, et al. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. *Lancet* 2012; 380(9836): 37–43.
- France EF, Wyke S, Gunn JM, et al. Multimorbidity in primary care: a systematic review of prospective cohort studies. *Br J Gen Pract* 2012; 62(597): e297–e307.
- Ryan BL, Allen B, Zwarenstein M, et al. Multimorbidity and mortality in Ontario, Canada: a population-based retrospective cohort study. *J Comorb* 2020; 10: 2235042X20950598.
- DuGoff EH, Canudas-Romo V, Buttorff C, et al. Multiple chronic conditions and life expectancy: a life table analysis. *Med Care* 2014; 52(8): 688–694.
- Roman Lay AA, Ferreira do Nascimento C, Caba Burgos F, et al. Gender differences between multimorbidity and all-cause mortality among older adults. *Curr Gerontol Geriatr Res* 2020; 2020: 7816785.
- Strauss VY, Jones PW, Kadam UT, et al. Distinct trajectories of multimorbidity in primary care were identified using latent class growth analysis. *J Clin Epidemiol* 2014; 67(10): 1163–1171.
- Lee SA, Joo S, Chai HW, et al. Patterns of multimorbidity trajectories and their correlates among Korean older adults. *Age Ageing* 2021; 50(4): 1336–1341.
- Vetrano DL, Grande G, Marengoni A, et al. Health trajectories in Swedish centenarians. *J Gerontol A Biol Sci Med Sci* 2021; 76(1): 157–163.
- Valderas JM, Starfield B, Sibbald B, et al. Defining comorbidity: implications for understanding health and health services. *Ann Fam Med* 2009; 7(4): 357–363.
- Pedersen CB. The Danish civil registration system. *Scand J Public Health* 2011; 39(7 Suppl): 22–25.
- Lynge E, Sandegaard JL and Rebolj M. The Danish national patient register. *Scand J Public Health* 2011; 39(7 Suppl): 30–33.
- Gjerstorff ML. The Danish cancer registry. *Scand J Public Health* 2011; 39(7 Suppl): 42–45.
- Mors O, Perto GP and Mortensen PB. The Danish psychiatric central research register. *Scand J Public Health* 2011; 39(7 Suppl): 54–57.
- Fortin M, Stewart M, Poitras ME, et al. A systematic review of prevalence studies on multimorbidity: toward a more uniform methodology. *Ann Fam Med* 2012; 10(2): 142–151.
- Baadsgaard M and Quitzau J. Danish registers on personal income and transfer payments. *Scand J Public Health* 2011; 39(7 Suppl): 103–105.
- Jensen VM and Rasmussen AW. Danish education registers. *Scand J Public Health* 2011; 39(7 Suppl): 91–94.
- Petersson F, Baadsgaard M and Thygesen LC. Danish registers on personal labour market affiliation. *Scand J Public Health* 2011; 39(7 Suppl): 95–98.
- Tonelli M, Wiebe N, Fortin M, et al. Methods for identifying 30 chronic conditions: application to administrative data. *BMC Med Inform Decis Mak* 2015; 15: 31.
- Diederichs C, Berger K and Bartels DB. The measurement of multiple chronic diseases—a systematic review on existing multimorbidity indices. *J Gerontol A Biol Sci Med Sci* 2011; 66(3): 301–311.
- Huntley AL, Johnson R, Purdy S, et al. Measures of multimorbidity and morbidity burden for use in primary care and community settings: a systematic review and guide. *Ann Fam Med* 2012; 10(2): 134–141.
- Le Reste JY, Nabbe P, Manceau B, et al. The European general practice research network presents a comprehensive definition of multimorbidity in family medicine and long term care, following a systematic review of relevant literature. *J Am Med Dir Assoc* 2013; 14(5): 319–325.
- Willadsen TG, Bebe A, Koster-Rasmussen R, et al. The role of diseases, risk factors and symptoms in the definition of multimorbidity - a systematic review. *Scand J Prim Health Care* 2016; 34(2): 112–121.
- Cortina-Borja M, Smith AD, Combarros O, et al. The synergy factor: a statistic to measure interactions in complex diseases. *BMC Res Notes* 2009; 2: 105.

32. Siggaard T, Reguant R, Jørgensen IF, et al. Disease trajectory browser for exploring temporal, population-wide disease progression patterns in 7.2 million Danish patients. *Nat Commun* 2020; 11(1): 4952.
33. Ashworth M, Durbaba S, Whitney D, et al. Journey to multimorbidity: longitudinal analysis exploring cardiovascular risk factors and sociodemographic determinants in an urban setting. *BMJ Open* 2019; 9(12): e031649.
34. Vetrano DL, Roso-Llorach A, Fernández S, et al. Twelve-year clinical trajectories of multimorbidity in a population of older adults. *Nat Commun* 2020; 11(1): 3223.
35. Prados-Torres A, Calderon-Larranaga A, Hanco-Saavedra J, et al. Multimorbidity patterns: a systematic review. *J Clin Epidemiol* 2014; 67(3): 254–266.
36. Ferrer A, Formiga F, Sanz H, et al. Multimorbidity as specific disease combinations, an important predictor factor for mortality in octogenarians: the Octabaix study. *Clin Interv Aging* 2017; 12: 223–231.
37. Schafer I, Kaduskiewicz H, Nguyen TS, et al. Multimorbidity patterns and 5-year overall mortality: Results from a claims data-based observational study. *J Comorb* 2018; 8(1): 2235042x18816588.
38. Caughey GE, Ramsay EN, Vitry AI, et al. Comorbid chronic diseases, discordant impact on mortality in older people: a 14-year longitudinal population study. *J Epidemiol Commun Health* 2010; 64(12): 1036–1042.
39. Vetrano DL, Palmer K, Marengoni A, et al. Frailty and multimorbidity: a systematic review and meta-analysis. *J Gerontol A Biol Sci Med Sci* 2018; 74: 659–666.
40. Landi F, Liperoti R, Russo A, et al. Disability, more than multimorbidity, was predictive of mortality among older persons aged 80 years and older. *J Clin Epidemiol* 2010; 63(7): 752–759.
41. Kudesia P, Salimrouny B, Stanley M, et al. The incidence of multimorbidity and patterns in accumulation of chronic conditions: a systematic review. *J Comorb* 2021; 11: 26335565211032880.
42. Momen NC, Plana-Ripoll O, Agerbo E, et al. Association between mental disorders and subsequent medical conditions. *N Engl J Med* 2020; 382(18): 1721–1731.
43. Vancampfort D, Correll CU, Gallinger B, et al. Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: a systematic review and large scale meta-analysis. *World Psychiat* 2016; 15(2): 166–174.
44. Chang CK, Hayes RD, Perera G, et al. Life expectancy at birth for people with serious mental illness and other major disorders from a secondary mental health care case register in London. *PLoS One* 2011; 6(5): e19590.
45. Penninx B and Lange SMM. Metabolic syndrome in psychiatric patients: overview, mechanisms, and implications. *Dialogues Clin Neurosci* 2018; 20(1): 63–73.
46. Berkson J. Limitations of the application of fourfold table analysis to hospital data. *Int J Epidemiol* 2014; 43(2): 511–515.
47. Nexoe J, Halvorsen PA and Kristiansen IS. Critiques of the risk concept—valid or not? *Scand J Public Health* 2007; 35(6): 648–654.
48. Reventlow S, Hvas AC and Tulinius C. really great danger the concept of risk in general practice. *Scand J Prim Health Care* 2001; 19(2): 71–75.
49. Willadsen TG, Siersma V, Nicolaisdottir DR, et al. Symptom burden in multimorbidity: a population-based combined questionnaire and registry study from Denmark. *BMJ Open* 2021; 11(4): e041877.
50. Hay MC. Reading sensations: understanding the process of distinguishing ‘fine’ from ‘sick’. *Transcultural Psychiat* 2008; 45(2): 198–229.
51. Eckerblad J, Theander K, Ekdahl AW, et al. Symptom trajectory and symptom burden in older people with multimorbidity, secondary outcome from the RCT AGE-FIT study. *J Adv Nurs* 2016; 72(11): 2773–2783.
52. Elnegaard S, Andersen RS, Pedersen AF, et al. Self-reported symptoms and healthcare seeking in the general population—exploring “the symptom iceberg”. *BMC Public Health* 2015; 15: 685.
53. Calderón-Larrañaga A and Fratiglioni L. Multimorbidity research at the crossroads: developing the scientific evidence for clinical practice and health policy. *J Intern Med* 2019; 285(3): 251–254.
54. Barnes PJ. Mechanisms of development of multimorbidity in the elderly. *Eur Respir J* 2015; 45(3): 790–806.
55. Ho IS, Azcoaga-Lorenzo A, Akbari A, et al. Examining variation in the measurement of multimorbidity in research: a systematic review of 566 studies. *Lancet Public Health* 2021; 6(8): e587–e597.
56. Lund Jensen N, Pedersen HS, Vestergaard M, et al. The impact of socioeconomic status and multimorbidity on mortality: a population-based cohort study. *Clin Epidemiol* 2017; 9: 279–289.
57. Thygesen LC and Ersboll AK. When the entire population is the sample: strengths and limitations in register-based epidemiology. *Eur J Epidemiol* 2014; 29(8): 551–558.
58. Smith SM, Wallace E, O’Dowd T, et al. Interventions for improving outcomes in patients with multimorbidity in primary care and community settings. *Cochrane Database Syst Rev* 2021; 1(1): Cd006560.
59. Rozing MP, Jønsson A, Køster-Rasmussen R, et al. The SOFIA pilot trial: a cluster-randomized trial of coordinated, co-produced care to reduce mortality and improve quality of life in people with severe mental illness in the general practice setting. *Pilot Feasibil Stud* 2021; 7(1): 168.